Company Focus
Moderna
Latest Moderna News
Biotechnology
Moderna has reported third-quarter 2024 revenues of $1.9 billion, marking a slight increase from the $1.8 billion posted in the same period in 2023. 7 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
Cue Biopharma (Nasdaq: CUE) has announced layoffs affecting about a quarter of its workforce, as part of a strategic overhaul to prioritize autoimmune programs and enhance operational efficiencies. 29 July 2024
Biosimilars
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has adopted positive opinions for six biosimilar medicines. 27 July 2024
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
Biotechnology
In the UK, the health technology assessor has ruled in favor of reimbursing a new use for Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab). 26 July 2024
Biotechnology
Belgian clinical-stage G-protein coupled receptor (GPCR) company Confo Therapeutics today announced the closing of a 60 million euros Series B financing 26 July 2024
Pharmaceutical
Bristol Myers Squibb was trading nearly 5% higher ahead of the opening bell on Friday. 26 July 2024
Biotechnology
An advisory panel of the US Food and Drug Administration has questioned the design of a trial for AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab), while confirming that it met the primary efficacy goal. 26 July 2024
Pharmaceutical
US drugmaker AbbVie was trading 3% higher early afternoon Thursday. 25 July 2024
Biotechnology
Californian drugmaker BioMarin Pharmaceutical (Nasdaq: BMRN) has announced that the US Food and Drug Administration has approved a label expansion for Brineura (cerliponase alfa). 25 July 2024
Pharmaceutical
French drugmaker Sanofi was trading more than 3% higher during Thursday afternoon’s trading in Paris. 25 July 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze